259 related articles for article (PubMed ID: 28267882)
1. Early conversion to belatacept after renal transplantation.
Nair V; Liriano-Ward L; Kent R; Huprikar S; Rana M; Florman SS; Delaney VB; Menon MC; Sehgal V; Miko L; Khaim R; Benvenisty A; Lerner S; Arvelakis A; Wadhera V; Ames S; Shapiro R
Clin Transplant; 2017 May; 31(5):. PubMed ID: 28267882
[TBL] [Abstract][Full Text] [Related]
2. Early post-transplant conversion from tacrolimus to belatacept for prolonged delayed graft function improves renal function in kidney transplant recipients.
Wojciechowski D; Chandran S; Vincenti F
Clin Transplant; 2017 May; 31(5):. PubMed ID: 28190259
[TBL] [Abstract][Full Text] [Related]
3. Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria Donors.
Le Meur Y; Aulagnon F; Bertrand D; Heng AE; Lavaud S; Caillard S; Longuet H; Sberro-Soussan R; Doucet L; Grall A; Legendre C
Am J Transplant; 2016 Jul; 16(7):2181-6. PubMed ID: 26718625
[TBL] [Abstract][Full Text] [Related]
4. Experience with belatacept rescue therapy in kidney transplant recipients.
Brakemeier S; Kannenkeril D; Dürr M; Braun T; Bachmann F; Schmidt D; Wiesener M; Budde K
Transpl Int; 2016 Nov; 29(11):1184-1195. PubMed ID: 27514317
[TBL] [Abstract][Full Text] [Related]
5. Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation.
Badell IR; Karadkhele GM; Vasanth P; Farris AB; Robertson JM; Larsen CP
Am J Transplant; 2019 Aug; 19(8):2342-2349. PubMed ID: 30768841
[TBL] [Abstract][Full Text] [Related]
6. Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function.
Adams AB; Goldstein J; Garrett C; Zhang R; Patzer RE; Newell KA; Turgeon NA; Chami AS; Guasch A; Kirk AD; Pastan SO; Pearson TC; Larsen CP
Am J Transplant; 2017 Nov; 17(11):2922-2936. PubMed ID: 28544101
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Conversion From Calcineurin Inhibitor to Belatacept-based Immunosuppression in HLA-sensitized Kidney Transplant Recipients.
Sethi S; Najjar R; Peng A; Choi J; Lim K; Vo A; Jordan SC; Huang E
Transplantation; 2020 Jul; 104(7):1500-1507. PubMed ID: 31568398
[TBL] [Abstract][Full Text] [Related]
8. Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept.
Choi M; Bachmann F; Wu K; Lachmann N; Schmidt D; Brakemeier S; Duerr M; Kahl A; Eckardt KU; Budde K; Nickel P
BMC Nephrol; 2020 Aug; 21(1):354. PubMed ID: 32819287
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
[TBL] [Abstract][Full Text] [Related]
10. Belatacept in renal transplant recipient with mild immunologic risk factor: A pilot prospective study (BELACOR).
Leibler C; Matignon M; Moktefi A; Samson C; Zarour A; Malard S; Boutin E; Pilon C; Salomon L; Natella PA; Durrbach A; Robert T; Canoui-Poitrine F; Grimbert P
Am J Transplant; 2019 Mar; 19(3):894-906. PubMed ID: 30582270
[TBL] [Abstract][Full Text] [Related]
11. Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism.
Schulte K; Vollmer C; Klasen V; Bräsen JH; Püchel J; Borzikowsky C; Kunzendorf U; Feldkamp T
J Nephrol; 2017 Aug; 30(4):607-615. PubMed ID: 28540602
[TBL] [Abstract][Full Text] [Related]
12. Belatacept Rescue Therapy in Kidney Transplant Recipients With Vascular Lesions: A Case Control Study.
Bertrand D; Cheddani L; Etienne I; François A; Hanoy M; Laurent C; Lebourg L; Le Roy F; Lelandais L; Loron MC; Godin M; Guerrot D
Am J Transplant; 2017 Nov; 17(11):2937-2944. PubMed ID: 28707779
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab induction and belatacept maintenance in marginal pathology renal allografts.
Sparkes T; Ravichandran B; Opara O; Ugarte R; Drachenberg CB; Philosophe B; Bromberg JS; Barth RN
Clin Transplant; 2019 Jun; 33(6):e13531. PubMed ID: 30866104
[TBL] [Abstract][Full Text] [Related]
14. Belatacept Conversion in an HIV-Positive Kidney Transplant Recipient With Prolonged Delayed Graft Function.
Ebcioglu Z; Liu C; Shapiro R; Rana M; Salem F; Florman S; Huprikar S; Nair V
Am J Transplant; 2016 Nov; 16(11):3278-3281. PubMed ID: 27328903
[TBL] [Abstract][Full Text] [Related]
15. Comparison of de novo IgM and IgG anti-HLA DSAs between belatacept- and calcineurin-treated patients: An analysis of the BENEFIT and BENEFIT-EXT trial cohorts.
Everly MJ; Roberts M; Townsend R; Bray RA; Gebel HM
Am J Transplant; 2018 Sep; 18(9):2305-2313. PubMed ID: 29767445
[TBL] [Abstract][Full Text] [Related]
16. Late Conversion to Belatacept After Kidney Transplantation: Outcome and Prognostic Factors.
Dürr M; Lachmann N; Zukunft B; Schmidt D; Budde K; Brakemeier S
Transplant Proc; 2017 Oct; 49(8):1747-1756.e1. PubMed ID: 28923620
[TBL] [Abstract][Full Text] [Related]
17. Early Conversion to Belatacept in Kidney Transplant Recipients With Low Glomerular Filtration Rate.
Abdelwahab Elhamahmi D; Heilman RL; Smith B; Huskey J; Khamash H; Kaplan B
Transplantation; 2018 Mar; 102(3):478-483. PubMed ID: 29077658
[TBL] [Abstract][Full Text] [Related]
18. Ten-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weekly.
Vincenti F; Blancho G; Durrbach A; Grannas G; Grinyó J; Meier-Kriesche HU; Polinsky M; Yang L; Larsen CP
Am J Transplant; 2017 Dec; 17(12):3219-3227. PubMed ID: 28758341
[TBL] [Abstract][Full Text] [Related]
19. Conversion to belatacept maintenance immunosuppression in HIV-positive kidney transplant recipients.
Santeusanio A; Bhansali A; De Boccardo G; Sehgal V; Delaney V; Florman S; Shapiro R
Clin Transplant; 2020 Oct; 34(10):e14041. PubMed ID: 32654239
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients.
Wen X; Casey MJ; Santos AH; Hartzema A; Womer KL
Am J Transplant; 2016 Nov; 16(11):3202-3211. PubMed ID: 27137884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
